DEBIOPHARM AND AURIGENE SIGN AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALISATION OF DEBIO 1142, A NOVEL INHIBITOR OF AN UNDISCLOSED ONCOLOGY PATHWAY
Debiopharm and Aurigene sign agreement for the development and commercialisation of Debio 1142, a novel inhibitor of an undisclosed oncology pathwayHello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing! SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA)
Aurigene Discovery Technologies Limited Announces Drug Discovery, Development, and Commercialization Partnership with EQRx
BENGALURU, India–(BUSINESS WIRE)–The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx’s pioneering business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory
Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies
SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research,
May 10 – 12, 2022, Adenosine-Pathway Targeted Cancer Immunotherapy Summit
Dual Targeting of CD73 & A2AR for Effective Suppression of Adenosine Signaling May 11 2022
April 18-22, 2022, Drug Discovery Chemistry
Small Molecule Modulators of the Tumor Micro-Environment April 19, 2022APRIL 8 – APRIL 13, 2022 American Association for Cancer Research (AACR) Annual Meeting
Presentation Title: AUR103 an oral small molecule CD47 antagonist in combination with azacytidine and bortezomib exhibits potent anti-tumor activity in myeloma and leukemia models in vitro and in vivohttps://www.abstractsonline.com/pp8/#!/10517/presentation/17070 Presentation